Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Sorrento Therapeutics, Inc is a biotechnology business based in the US. Sorrento Therapeutics shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therapeutics employs 310 staff and has a trailing 12-month revenue of around USD$35.5 million.
Since the stock market crash in March caused by coronavirus, Sorrento Therapeutics's share price has had significant positive movement.
Its last market close was USD$9.3, which is 72.69% up on its pre-crash value of USD$2.54 and 500.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.55.
If you had bought USD$1,000 worth of Sorrento Therapeutics shares at the start of February 2020, those shares would have been worth USD$554.05 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,513.51.
|Latest market close||USD$9.3|
|52-week range||USD$1.45 - USD$15.04|
|50-day moving average||USD$9.2506|
|200-day moving average||USD$6.9694|
|Wall St. target price||USD$25.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.404|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-23)||15.10%|
|1 month (2020-10-01)||-13.00%|
|3 months (2020-07-30)||8.77%|
|6 months (2020-04-30)||309.69%|
|1 year (2019-10-30)||515.89%|
|2 years (2018-10-30)||197.12%|
|3 years (2017-10-30)||257.69%|
|5 years (2015-10-30)||7.64%|
|Revenue TTM||USD$35.5 million|
|Gross profit TTM||USD$-87,684,000|
|Return on assets TTM||-20.42%|
|Return on equity TTM||-443.24%|
|Market capitalisation||USD$2.2 billion|
TTM: trailing 12 months
There are currently 75.7 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 0.8% up from 75.1 million last month.
There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.
Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 32.4 million). Sorrento Therapeutics's SIR currently stands at 2.34. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 2340 shares are currently held short.
However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.29% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 290 shares are currently held short) or 0.2947% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 295 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sorrento Therapeutics.
Find out more about how you can short Sorrento Therapeutics stock.
We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.
Sorrento Therapeutics's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.
Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as $1.45 up to $15.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.6089. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Everything we know about the EZGO Technologies IPO, plus information on how to buy in.
Everything we know about the NeoGames IPO, plus information on how to buy in.
Everything we know about the Genius Sports Group Ltd IPO, plus information on how to buy in.
Everything we know about the Meat-Tech 3D IPO, plus information on how to buy in.
Everything we know about the Monday.com IPO, plus information on how to buy in.
Everything we know about the Maravai LifeSciences Holdings IPO, plus information on how to buy in.
Everything we know about the WeWork IPO, plus information on how to buy in.
Steps to owning and managing RAVN, with 24-hour and historical pricing before you buy.
Steps to owning and managing NBIX, with 24-hour and historical pricing before you buy.
Steps to owning and managing KTB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.